Scott Rocklage on life science investments

Dr. Scott M. Rocklage is a Ph.D. holder. He acquired his B.S in chemistry from the University of California and his chemistry Ph.D. from Massachusetts Institute of technology. In 2003 Dr. Rocklage joined the 5 AM Ventures as a Venture Partner. In 2004 he became the managing partner. Dr. Rocklage has over 20 years’ experience in healthcare management and his strategic leadership qualities have seen to the approval of three United States new drugs applications by the Food and Drug Administration (Teslascan®, Cubicin®, and Omniscan™) and helped several drug candidates enter into clinical trials. Dr. Rocklage is an inventor and co-inventor of more than 30 United States patents and over 100 peer-reviewed issues.

 

Dr. Rocklage once served as CEO and president of Nycomed Salutar, CEO, and chairman of Cubist Pharmaceuticals, chairman, and CEO of Nycomed interventional. He also held research and development positions in Catalytica and salutar. Dr. Rocklage previously served as the chairman of the board in Novira and Relypsa. And an executive chairman of Semprus, Miikana, and Ilypsa. Currently, he is the chairman board of Cidara, Rennovia, and Kinestral. He also serves on Epirus and Pulmatrix boards.

 

Dr. Rocklage started his life science-based venture business and named it 5 AM ventures because the company formation was thought to be in early stage. He spends most of his days studying life science and other days doing his managerial roles in various companies and works with entrepreneurs like physicians, business executives or scientist to help them shape their ideas onto potential medicine that will help to meet the medical needs that are unmet.

 

As a productive entrepreneur, Dr. Rocklage is well organized regarding calendaring, prioritization and time management. His most significant advice to his fellow entrepreneurs is that “you should not be afraid of taking measured risks for you do better when you have control of your future through entrepreneurship than when working for established companies. He also advises that if you learn you had hired a wrong person, move swiftly and don’t consider goals and performance review as the best way to change the person’s performance nature. According to Dr. Rocklage, web services and software do not have any impact on life science investing.

 

Connect with Dr. Scott Rocklage on LinkedIn.